Gestational trophoblastic disease is a general term used to designate changes originating from the abnormal proliferation of the trophoblast, which includes the hydatidiform mole, invasive moles, placental site trophoblastic tumor and choriocarcinoma, among others less frequent. This revision aims to show gestational trophoblastic diseases, focusing on choriocarcinoma, besides presenting substances from plants tested in this cancer. Choriocarcinoma is formed by a proliferation of cytotrophoblasts and syncytiotrophoblasts, characterized by abnormal trophoblastic hyperplasia and anaplasia, absence of chorionic villi, hemorrhage and necrosis. The choriocarcinoma occurs after a hydatidiform mole in spontaneous abortions, ectopic pregnancies, and normal full-term pregnancies. Its occurrence is also described in men, originated from testicular germ cell tumors. In women, a preexisting hydatidiform mole, evaluation of elevate hCG levels not associated with pregnancy, ultrasonography and anatomopathological examination are important in the diagnosis. In most cases of choriocarcinoma and other gestational trophoblastic neoplasia, the treatment using chemotherapy drugs is the most used. Moreover, many isolated substances, identified and/or synthetized, from medicinal plants, have been tested and may be sources of future drugs to act directly or indirectly on treatment or prevention of these diseases. The results of recent research with plantderived molecules show inhibition mechanisms of cell proliferation and cell viability similar to those used in current regimes. This reveals the importance of continuing to carry out researches that present biochemical and molecular aspects of choriocarcinoma, such as action of treatment or prevention drugs, as well as further studies regarding substances with therapeutic potential and lower adverse effects.